The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 26, 2016
Filed:
Nov. 13, 2013
Applicant:
Mannkind Corporation, Valencia, CA (US);
Inventors:
John Bruce Patterson, Ventura, CA (US);
David Gregory Lonergan, Ventura, CA (US);
Gary A. Flynn, Tucson, AZ (US);
Qingping Zeng, Thousand Oaks, CA (US);
Peter V. Pallai, Carlsbad, CA (US);
Assignee:
MannKind Corporation, Valencia, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); C07C 47/55 (2006.01); C07C 47/565 (2006.01); C07C 47/575 (2006.01); C07D 213/64 (2006.01); C07D 213/69 (2006.01); C07D 213/74 (2006.01); C07D 217/16 (2006.01); C07D 231/12 (2006.01); C07D 239/26 (2006.01); C07D 239/54 (2006.01); C07D 261/08 (2006.01); C07D 277/34 (2006.01); C07D 295/192 (2006.01); C07D 307/80 (2006.01); C07D 317/54 (2006.01); C07D 319/18 (2006.01); C07D 321/10 (2006.01); C07D 333/22 (2006.01); C07D 333/58 (2006.01); C07D 417/10 (2006.01); A61K 31/11 (2006.01); A61K 31/135 (2006.01); A61K 31/192 (2006.01); A61K 31/357 (2006.01); A61K 31/381 (2006.01); A61K 31/505 (2006.01); A61K 31/5375 (2006.01); C07C 65/30 (2006.01); C07C 205/44 (2006.01); C07D 295/125 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/11 (2013.01); A61K 31/135 (2013.01); A61K 31/192 (2013.01); A61K 31/357 (2013.01); A61K 31/381 (2013.01); A61K 31/505 (2013.01); A61K 31/5375 (2013.01); C07C 47/55 (2013.01); C07C 47/565 (2013.01); C07C 47/575 (2013.01); C07C 65/30 (2013.01); C07C 205/44 (2013.01); C07D 213/64 (2013.01); C07D 213/69 (2013.01); C07D 213/74 (2013.01); C07D 217/16 (2013.01); C07D 231/12 (2013.01); C07D 239/26 (2013.01); C07D 239/54 (2013.01); C07D 261/08 (2013.01); C07D 277/34 (2013.01); C07D 295/125 (2013.01); C07D 295/192 (2013.01); C07D 307/80 (2013.01); C07D 317/54 (2013.01); C07D 319/18 (2013.01); C07D 321/10 (2013.01); C07D 333/22 (2013.01); C07D 333/58 (2013.01); C07D 417/10 (2013.01);
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.